Vivus Cleared For Amended Ch. 11 Plan With Drug Royalties
Biotech company Vivus Inc. received approval Thursday for an amended Chapter 11 plan that provides additional recoveries for existing shareholders through a drug sale royalty settlement, after a Delaware judge rejected...To view the full article, register now.
Already a subscriber? Click here to view full article